Switch theme
Sign up to access all valuation multiples
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
2018
362
LTM Revenue $2.8M
LTM EBITDA -$450M
$2.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Immunovant has a last 12-month revenue (LTM) of $2.8M and a last 12-month EBITDA of -$450M.
In the most recent fiscal year, Immunovant achieved revenue of n/a and an EBITDA of -$438M.
Immunovant expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Immunovant valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.8M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$450M | XXX | -$438M | XXX | XXX | XXX |
| EBITDA Margin | -15961% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$458M | XXX | -$438M | XXX | XXX | XXX |
| EBIT Margin | -16244% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$437M | XXX | -$414M | XXX | XXX | XXX |
| Net Margin | -15483% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 17, 2025, Immunovant's stock price is $18.
Immunovant has current market cap of $3.0B, and EV of $2.3B.
See Immunovant trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.3B | $3.0B | XXX | XXX | XXX | XXX | $-2.77 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 17, 2025, Immunovant has market cap of $3.0B and EV of $2.3B.
Immunovant's trades at n/a EV/Revenue multiple, and -5.9x EV/EBITDA.
Equity research analysts estimate Immunovant's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Immunovant has a P/E ratio of -7.0x.
See valuation multiples for Immunovant and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.0B | XXX | $3.0B | XXX | XXX | XXX |
| EV (current) | $2.3B | XXX | $2.3B | XXX | XXX | XXX |
| EV/Revenue | 826.7x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -5.2x | XXX | -5.9x | XXX | XXX | XXX |
| EV/EBIT | -5.1x | XXX | -5.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -7.0x | XXX | -8.1x | XXX | XXX | XXX |
| EV/FCF | -5.9x | XXX | -6.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialImmunovant's last 12 month revenue growth is 1097%
Immunovant's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.2M for the same period.
Immunovant's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Immunovant's rule of X is -13219% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Immunovant and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1097% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -15961% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 4% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -13219% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Immunovant acquired XXX companies to date.
Last acquisition by Immunovant was XXXXXXXX, XXXXX XXXXX XXXXXX . Immunovant acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Immunovant founded? | Immunovant was founded in 2018. |
| Where is Immunovant headquartered? | Immunovant is headquartered in United States of America. |
| How many employees does Immunovant have? | As of today, Immunovant has 362 employees. |
| Who is the CEO of Immunovant? | Immunovant's CEO is Dr. Eric Venker, M.D.,Pharm.D.. |
| Is Immunovant publicy listed? | Yes, Immunovant is a public company listed on NAS. |
| What is the stock symbol of Immunovant? | Immunovant trades under IMVT ticker. |
| When did Immunovant go public? | Immunovant went public in 2019. |
| Who are competitors of Immunovant? | Similar companies to Immunovant include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Immunovant? | Immunovant's current market cap is $3.0B |
| What is the current revenue of Immunovant? | Immunovant's last 12 months revenue is $2.8M. |
| What is the current revenue growth of Immunovant? | Immunovant revenue growth (NTM/LTM) is 1097%. |
| What is the current EV/Revenue multiple of Immunovant? | Current revenue multiple of Immunovant is 826.7x. |
| Is Immunovant profitable? | Yes, Immunovant is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Immunovant? | Immunovant's last 12 months EBITDA is -$450M. |
| What is Immunovant's EBITDA margin? | Immunovant's last 12 months EBITDA margin is -15961%. |
| What is the current EV/EBITDA multiple of Immunovant? | Current EBITDA multiple of Immunovant is -5.2x. |
| What is the current FCF of Immunovant? | Immunovant's last 12 months FCF is -$397M. |
| What is Immunovant's FCF margin? | Immunovant's last 12 months FCF margin is -14059%. |
| What is the current EV/FCF multiple of Immunovant? | Current FCF multiple of Immunovant is -5.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
